Don’t let the high cost of brand chronic hepatitis C therapy disrupt your treatment. We help eligible patients access Sovaldi (sofosbuvir) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Sovaldi Prescription Assistance Program is a manufacturer-sponsored initiative that provides Sovaldi at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for chronic hepatitis C patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, hepatologist or HCV provider coordination, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and treatment-course completion.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$26,000 | Save ~$25,930/mo |
| CVS Pharmacy | ~$28,000 | Save ~$27,930/mo |
| Walmart | ~$22,000 | Save ~$21,930/mo |
| Costco | ~$21,000 | Save ~$20,930/mo |
Generic sofosbuvir/velpat. | ~$24,000 | Authorized generic |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Sovaldi at no medication cost if approved. Our $69.95/month service covers full advocacy. With authorized generic combinations widely available, we’ll help your provider determine the best HCV regimen and the lowest-cost path.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Sovaldi:
Still $20,000–$28,000 per month even with the best discount
discount
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Sovaldi assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Sovaldi (sofosbuvir) is a once-daily direct-acting antiviral (DAA) used as a component of combination therapy for chronic hepatitis C. It is an HCV NS5B polymerase inhibitor with pan-genotypic activity.
How Sovaldi Works:
Sofosbuvir is a nucleotide analog that targets the NS5B polymerase, an enzyme the Hepatitis C virus needs to replicate its RNA. Once absorbed into liver cells, it integrates into the viral RNA chain and terminates further synthesis. To achieve high cure rates within 8–12 weeks, it is typically paired with other direct-acting antivirals to effectively halt the replication process.
Form and use:
Sovaldi is administered as a single 400 mg tablet taken once daily, with or without food. While it can be taken as a standalone pill, it is most commonly used as part of a fixed-dose combination like Epclusa or Harvoni for a standard treatment duration of 8–12 weeks. Most patients achieve a complete cure after finishing a single course of therapy.
Generic availability:
Authorized generic versions of sofosbuvir-containing combinations are widely available at a significantly lower cost than their brand-name counterparts. These generics have largely replaced brand-name Sovaldi and Harvoni for new treatment starts. Other alternatives include Mavyret, a combination drug often used for an 8-week course in patients who have not been treated previously.
Warnings:
A critical warning for Sovaldi is the risk of Hepatitis B reactivation in co-infected patients, making HBV testing mandatory before starting treatment to prevent potentially fatal liver flares. It is also associated with serious bradycardia when used alongside amiodarone. Additionally, certain medications and supplements, such as rifampin or St. John’s wort, can interact with the drug and reduce its effectiveness.
Sovaldi costs approximately $20,000–$28,000 per 28-day supply, with a full course commonly $80,000–$120,000+. Through AffordMyPrescriptions, qualifying patients receive Sovaldi at no medication cost — our $69.95 monthly fee covers full advocacy and program management. Authorized generic combinations (generic Epclusa, generic Harvoni) are also widely available at lower cost.
Yes, in most cases. Sofosbuvir-based combination DAA therapy (Epclusa, Harvoni, with or without ribavirin) cures over 95% of HCV patients in 8–12 weeks. ‘Cure’ in HCV means sustained virologic response 12 weeks after completing therapy (SVR12) — a durable, treatment-ending outcome.
HCV develops resistance very quickly when treated with a single DAA. Combination therapy (sofosbuvir + velpatasvir, or sofosbuvir + ledipasvir, or other combinations) delivers complementary antiviral pressure that prevents resistance and achieves cure. Most patients receive sofosbuvir as part of a fixed-dose combination tablet rather than as standalone Sovaldi
Yes. The FDA requires generics and authorized generics to be bioequivalent to brand. Generic sofosbuvir/velpatasvir (Epclusa equivalent) has the same active ingredients at the same doses, and is widely accepted as clinically equivalent. It is often substantially cheaper.
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays you cannot afford for the duration of therapy.
Tell your prescriber. HCV treatment with DAAs can cause severe hepatitis B reactivation in patients with chronic HBV. HBV testing is required before starting, and HBV co-infection requires a coordinated treatment plan.
If denied, we explore alternatives — switching to authorized generic sofosbuvir/velpatasvir (generic Epclusa), generic ledipasvir/sofosbuvir, or Mavyret (each often less expensive), state Medicaid for chronic HCV (now widely covered), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the PAN Foundation or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee
If you are struggling with the high cost of Sovaldi, our team may be able to help you access assistance programs designed to make brand HCV cures affordable. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.